Good set of FY24 results, slightly above expectations at the operating result level.

Beat on FY24 results but guidance is disappointing.

Solid 24 results and decent 25 Guidance.

Novo Nordisk

Beat on 24 numbers - Somewhat weak guidance could prompt consensus downgrade.

Beat on FY results but weak guidance for 25 and a cost cutting plan